At present, the clinical treatment of Alzheimer’s disease and memory deficits includes acetylcholines such as Ach prodrugs, cholinesterase inhibitor-tacrine, piracetam for enhancing brain metabolism, Glutamate receptor modulator-Mematitine, Nicergoine for inhibiting platelet aggregation and calcium antagonist-Nimodipine (Pantoni., 2004; Farooq, et al., 2017). The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.